New TB Antibiotics Target Bacteria’s Protein Recycling, Offering Hope Against Drug-Resistant TB
Researchers analyzed three experimental anti-TB compounds—ecumicin, ilamycins, and cyclomarins—and found they all disrupt the M. tuberculosis protein-recycling machine ClpC1-ClpP1P2, each in a different way, causing widespread disturbances across thousands of bacterial proteins and triggering stress responses (ecumicin notably raises Hsp20). This mechanistic mapping provides a clearer path to designing more precise anti-TB drugs as drug-resistant TB remains a major global threat; the work was published in Nature Communications.